glutathione and the liver in diseases hepatotoxicity Glutathione in the Treatment of

Although anecdotal reports indicate BPC-157 to be a non-toxic peptide with few adverse interactions, further long-term research is required for the FDA to concur with such a notion

Also known as Body Protection Compound-157, it is composed of 15 amino acids and is considered a peptidergic agent, meaning it has drug-like effects

However, the narrow therapeutic time window greatly limits both the efficacy and safety of these interventions ( However, despite promising preclinical results, the clinical translation of SIN is limited by its poor pharmacokinetic profile, including low oral bioavailability and rapid systemic clearance

Ireland, R

1 ), clinically ( Figs